TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06378879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 100 MG in 10 ML Injection
Description: Sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes), any involuntary patient movement, quality of sedation (VAS) and adverse events

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 100 MG in 10 ML Injection
Description: Sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes), any involuntary patient movement, quality of sedation (VAS) and adverse events
Study: NCT05603026

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expanding valve (Medtronic Evolut FX)
Description: Bioprothesis Medtronic Evolut FX supra-annular self-expanding valve
Study: NCT05420727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-PSMA-11 PET/CT
Description: Ga-68-PSMA-11 PET/CT imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-ITG-PSMA-1
Description: Lu-177-ITG-PSMA-1 treatment
Study: NCT04769856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: State-Trait Anxiety Inventory (STAI) scale
Description: State-Trait Anxiety Inventory (STAI) scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: State-Trait Anxiety Inventory (STAI) scale
Description: State-Trait Anxiety Inventory (STAI) scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction scale
Description: Satisfaction scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction scale
Description: Satisfaction scale
Study: NCT03903601

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples collection
Description: Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples collection
Description: Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Cognitive functions assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Cognitive functions assessment
Study: NCT06662123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Participants will receive a single SC or IV dose of anifrolumab at day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Participants will receive a single SC or IV dose of anifrolumab at day 1
Study: NCT06671600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative medicine
Description: osteopathic manipulative treatment protocol will be applied to the cranial, cervical, thoracic, and ribcage regions. OMM procedures performed on the treatment group will consist of 1. suboccipital decompression/release, 2. base spread, 3. occipitoatlantal (OA) decompression, 4. venous sinus drainage, 5. compression of the fourth ventricle, 6. cervical myofascial (unilateral perpendicular stretch), 7. thoracic inlet release (direct or indirect), 8. Bilateral rib raising, 9. thoracoabdominal diaphragm doming (direct technique), and 10. pedal pump (Dalrymple lymphatic pump)
Study: NCT04743349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Steam inhalations
Description: Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
Study: NCT06448182

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic
Description: 1 capsule of postbiotic daily in the morning
Study: NCT05603026

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-expanding valve (Edwards Sapien 3 Ultra)
Description: Bioprosthesis Edwards Sapien 3 Ultra valve
Study: NCT06448182

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule of placebo daily in the morning
Study: NCT06671600

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The sham group will serve as the control group and will receive a light touch-control procedure based on prior study utilizing light touch.
Study: NCT06611748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Key Grip
Description: KeyGrip is an implantable peripheral nerve stimulator that is being studied for its ability to provide coordinated activation of innervated paralyzed muscles. KeyGrip will be configured to activate nerves of the upper extremity (arm and hand) in order to facilitate movements such as hand opening and/or closing
Study: NCT06674096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLC-CRCHOP
Description: Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11
Study: NCT06672536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT520FF
Description: SCT520FF dose level 1，IVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT520FF
Description: SCT520FF dose level 2，IVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT520FF
Description: SCT520FF dose level 3，IVI
Study: NCT06217536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given intravenously (IV)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conventionally fractionated radiotherapy or external beam radiation
Study: NCT05639465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JoH-C19
Description: Journey of Hope- COVID 19 (JoH-C19) includes eight, 1-hour consecutive sessions delivered in groups of 8 children during the school day and in after school settings. The 1.5 hour JoH-C19 caregiver workshop is delivered with groups of 8 parents prior to the child JoH-C19 curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Switch off Get Active
Description: Switch off Get Active covers 4 topics, and its eight, 1- hour sessions are delivered in groups of 8 children. The 1.5 hour Switch Off Get Active caregiver workshop is delivered with groups of 8 parents prior to the Switch off Get Active child curriculum
Study: NCT05358015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vascularized bone graft for scaphois nonunion
Description: vascularized bone graft for scaphois nonunion
Study: NCT05773703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA-Targeted [In-111]-Labeled Trillium Compound
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA-Targeted [In-111]-Labeled Trillium Compound
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA-Targeted [In-111]-Labeled Trillium Compound
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-122
Description: Cytoprotective agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-122
Description: Cytoprotective agent
Study: NCT06217536

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conventionally fractionated radiotherapy or external beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conventionally fractionated radiotherapy or external beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conventionally fractionated radiotherapy or external beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conventionally fractionated radiotherapy or external beam radiation
Study: NCT05720351

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lachmann maneuver
Description: Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staircase maneuver
Description: Patients undergone Undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
Study: NCT06569849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress and Focus capsule- U001
Description: Two capsules in sequence daily after meal for 60 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress and Focus capsule - I001
Description: Two capsules in sequence daily after meal for 60 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules 001
Description: Two capsules in sequence daily after meal for 60 days.
Study: NCT05424276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IkT-148009
Description: Oral administration gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IkT-148009
Description: Oral administration gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IkT-148009
Description: Oral administration gelatin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration gelatin capsule
Study: NCT06215157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flotrac Group
Description: Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioZ Group
Description: Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
Study: NCT06101485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation platform: Hjerteportalen, blood pressure monitor (iHealth(neo/BP5s), weight scale (iHealth Lina), Activity tracker (FitBit inspire 3), ECG monitor (AliveCor KardiaMobile), sleep sensor (Emfit QS), video consultation (VDX by MedCom)
Study: NCT05426083

Intervention type: OTHER
Intervention: Physiological Assessment
Description: Observational only
Study: NCT06541587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness based virtual reality
Description: mindfulness based virtual reality

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness based audio practice
Description: mindfulness based audio practice
Study: NCT05613946

Intervention type: DRUG
Group type: OTHER
Intervention: Lumason
Description: Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity

Intervention type: DRUG
Group type: OTHER
Intervention: Optison
Description: Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity

Intervention type: DRUG
Group type: OTHER
Intervention: Definity
Description: Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
Study: NCT05321745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized FMT
Description: Fecal microbiota transplantation of fresh bacteria from healthy donor to the whole colon
Study: NCT06332755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-LR1109
Description: intravenous administration
Study: NCT04918771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raphamin
Description: Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.~On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration - not with food. Placebo using Raphamin scheme.
Study: NCT05896826

Intervention type: DEVICE
Intervention: Magnetometer
Description: inspection equipment for magnetocardiography

Intervention type: DEVICE
Intervention: Magnetometer
Description: inspection equipment for magnetocardiography
Study: NCT04942470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloe vera and propolis applied
Description: Suitable of sterile pads containing aloe vera and propolis to the area with pressure sores
Study: NCT05298670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 1000 Mg Oral Tablet
Description: Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Disease Modifying Therapies (DMTs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Disease Modifying Therapies (DMTs)
Study: NCT05778851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EsoGuard result
Description: Education slide-set EsoGuard and patient cases including EsoGuard result

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EsoGuard result
Description: Education slide-set EsoGuard and patient cases including EsoGuard result

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EsoGuard result
Description: Education slide-set EsoGuard and patient cases including EsoGuard result
Study: NCT06221774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 + Toripalimab
Description: TT-00420 tablets in combination with Toripalimab injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 + Toripalimab
Description: TT-00420 tablets in combination with Toripalimab injection
Study: NCT06416085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
Study: NCT05356026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online postpartum follow-up
Description: The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
Study: NCT06466096

Intervention type: OTHER
Intervention: no intervention
Description: this is an observation study, no intervention
Study: NCT05841771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine or decitabine
Description: azacytidine 32mg/m2 or decitabine 5mg/m2
Study: NCT06391333

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laryngeal mask airway and endotracheal tube
Description: The two most commonly used devices for mechanical ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask airway and endotracheal tube
Description: The two most commonly used devices for mechanical ventilation.
Study: NCT05937802

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Osmotin
Description: Oral administration for 6 months of 7 capsules per day (4 in the morning and 3 in the evening) for a daily dosage of 5 grams.
Study: NCT05281575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Friendly Spaces (BFS)
Description: Designed to meet the unique needs of populations living in humanitarian contexts, BFS focus on two domains: psychosocial support that targets maternal wellbeing and childcare practices that target caregiver functioning to also address child wellbeing and development. In so doing, BFS strengthens mothers' internal resources and skills in caring for their children both in quantity (time spent caring for the child) and quality (responsiveness), to positively impact the health status and wellbeing of their children. In BFS, the following activities are delivered by trained psychosocial workers: counselling for infant and young child feeding practices; hygiene education and promotion; mother-child bonding activities that provide psychosocial stimulation essential for children at risk of, or experiencing, malnutrition; and provision of maternal psychosocial support (i.e. psychoeducation, stress management).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby Friendly Spaces (BFS)
Description: Designed to meet the unique needs of populations living in humanitarian contexts, BFS focus on two domains: psychosocial support that targets maternal wellbeing and childcare practices that target caregiver functioning to also address child wellbeing and development. In so doing, BFS strengthens mothers' internal resources and skills in caring for their children both in quantity (time spent caring for the child) and quality (responsiveness), to positively impact the health status and wellbeing of their children. In BFS, the following activities are delivered by trained psychosocial workers: counselling for infant and young child feeding practices; hygiene education and promotion; mother-child bonding activities that provide psychosocial stimulation essential for children at risk of, or experiencing, malnutrition; and provision of maternal psychosocial support (i.e. psychoeducation, stress management).
Study: NCT05182099

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liver MRI
Description: Gd-EOB-DTPA enhanced MRI consists of T2-weighted image (T2WI), diffusion weighted image (DWI) and precontrast T1-weighted image (T1WI), dynamic T1WI (arterial, portal and transitional phases), and hepatobiliary phase.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Liver MRI
Description: Gd-EOB-DTPA enhanced MRI consists of T2-weighted image (T2WI), diffusion weighted image (DWI) and precontrast T1-weighted image (T1WI), dynamic T1WI (arterial, portal and transitional phases), and hepatobiliary phase.
Study: NCT05577403

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan's mobilization with movement MWM added isometric strength training
Description: Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd \& 4th week of intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement MWM added isometric strength training
Description: Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd \& 4th week of intervention.
Study: NCT06498531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Study: NCT05630339

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium chloride
Description: Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inert placebo
Description: Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
Study: NCT00013234

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Teledermatology
Study: NCT05133076

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus gasseri BGP345A
Description: Active and placebo capsules for oral use

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04996641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment and crown
Description: Pre-radiation one day root canal treatment and CAD/CAM chair side fabricated crowns for head and neck cancer patients